Everolimus
Back to searchMolecule Structure
Scientific Name
Everolimus
Description of the Drug
Everolimus is a mammalian target of rapamycin (mTOR) kinase inhibitor used to treat various types of malignancies.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB01590
http://www.drugbank.ca/drugs/DB01590
Brand Name(s)
Afinitor, Afinitor disperz, Certican, Votubia, Zortress
Company Owner(s)
Teva Pharmaceuticals Usa Inc, Alkem Laboratories Ltd, Par Pharmaceutical, Novartis Pharmaceutical Corp, Mylan Pharmaceuticals Inc, Biocon Pharma Ltd, Novartis Pharmaceuticals Corp, Hikma Pharmaceuticals Usa Inc, Breckenridge Pharmaceutical Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| FK506-binding protein 1A | SINGLE PROTEIN | INHIBITOR | CHEMBL1902 |
Clinical Trial(s)
Unichem Links
| Atlas | RAD001 | ||
| SureChEMBL | SCHEMBL20973097 | SCHEMBL4378 | |
| PharmGKB | PA164746311 | ||
| DrugBank | DB01590 | ||
| PubChem: Thomson Pharma | 14767667 | 14865574 | |
| PubChem | 6442177 | ||
| LINCS | LSM-43172 | ||
| BindingDB | 50088378 | ||
| EPA CompTox Dashboard | DTXSID0040599 | ||
| DrugCentral | 1118 | ||
| ChemicalBook | CB9502411 | ||
| Guide to Pharmacology | 5889 | ||
| rxnorm | AFINITOR | EVEROLIMUS | ZORTRESS |
| PubChem: Drugs of the Future | 12014881 | ||
| ChEBI | 68478 | ||
| ZINC | ZINC000169677008 |
